CareDx’s (CDNA) Overweight Rating Reiterated at Stephens

Stephens reiterated their overweight rating on shares of CareDx (NASDAQ:CDNA) in a research note released on Thursday morning,Benzinga reports. Stephens currently has a $40.00 price objective on the stock.

Other equities analysts also recently issued reports about the company. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and lowered their price objective for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. StockNews.com raised shares of CareDx from a “hold” rating to a “buy” rating in a research report on Wednesday. BTIG Research cut their price target on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, November 5th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $26.00 price objective on shares of CareDx in a report on Tuesday, January 14th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $32.00.

CareDx Stock Down 0.2 %

NASDAQ:CDNA opened at $21.06 on Thursday. CareDx has a 52 week low of $7.42 and a 52 week high of $34.84. The stock’s fifty day moving average is $22.65 and its two-hundred day moving average is $25.29. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -7.80 and a beta of 1.87.

CareDx (NASDAQ:CDNA) last released its earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The company had revenue of $86.58 million for the quarter, compared to analyst estimates of $84.56 million. On average, sell-side analysts expect that CareDx will post -0.9 EPS for the current fiscal year.

Institutional Trading of CareDx

Several institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning purchased a new position in shares of CareDx during the third quarter worth approximately $204,000. Hanseatic Management Services Inc. acquired a new stake in shares of CareDx during the third quarter worth about $781,000. Principal Financial Group Inc. acquired a new stake in shares of CareDx during the third quarter worth about $557,000. KBC Group NV purchased a new position in shares of CareDx during the third quarter worth about $99,000. Finally, Royce & Associates LP increased its position in CareDx by 0.3% in the 3rd quarter. Royce & Associates LP now owns 393,286 shares of the company’s stock valued at $12,280,000 after acquiring an additional 1,000 shares during the period.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.